Chemotherapy dose reduction and delay in clinical practice
- 1 April 2000
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 36, 11-14
- https://doi.org/10.1016/s0959-8049(99)00259-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.Journal of Clinical Oncology, 1998
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalThe Lancet, 1996
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Understanding Adjuvant Chemotherapy for Breast CancerNew England Journal of Medicine, 1994
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988